Researcher Wins 2026 Broermann Medical Innovation Award

Richard DiMarchi shares the honor with two co-recipients for work advancing peptide hormone drugs for obesity and diabetes.

Updated on Nov. 19, 2026 in Diabetes

Researcher Wins 2026 Broermann Medical Innovation Award

Richard DiMarchi, a distinguished professor of chemistry at Indiana University, received the 2026 Broermann Medical Innovation Award at a ceremony in Wiesbaden, Germany. He shares the award with Svetlana Mojsov of The Rockefeller University and Matthias H. Tschöp, president of Ludwig Maximilian University in Munich.

Why it matters

The award recognizes research with significant impact on human health. DiMarchi's work helped establish chemically enhanced peptide hormones as drugs, broadening treatment options for obesity, diabetes and other endocrine diseases.

The award is presented to three researchers jointly, with no quantitative efficacy or sample-size figures provided in the source material. The specific clinical metrics underlying the recognized work remain unstated in the available extraction.

The players

Richard DiMarchi

A distinguished professor of chemistry and Gill Chair in biomolecular sciences at Indiana University, known for research on peptide hormone therapeutics.

Svetlana Mojsov

A researcher at The Rockefeller University who shares the 2026 Broermann Medical Innovation Award with DiMarchi.

Matthias H. Tschöp

President of Ludwig Maximilian University in Munich, Germany, and a co-recipient of the 2026 Broermann Medical Innovation Award.

The details

DiMarchi was honored for pioneering and promoting chemically enhanced peptide hormones as drugs. The award was presented at a ceremony in Wiesbaden, Germany, and recognizes research breakthroughs in treating obesity and diabetes.

Timeline

  1. - Nov. 17, 2026: Broermann Medical Innovation Award presented at ceremony in Wiesbaden, Germany.

Health Landscape

The recognition sits within the wave of peptide-hormone drug development that produced GLP-1 receptor agonists for diabetes and obesity. It spotlights the chemistry-driven approach that expanded treatment options for endocrine disease beyond earlier therapies.

Advances in peptide-hormone drugs can expand the range of treatments available to people living with obesity and diabetes. Patients and clinicians may see new options as this research moves toward clinical use, though the extraction does not specify timelines.

The takeaway

Recognition of peptide-hormone research highlights how chemical innovation can produce new drug classes for chronic metabolic disease. Readers tracking diabetes and obesity treatments can watch for further clinical developments from this line of work.

Further reading

Explore more on Diabetes to see how peptide hormone research is shaping current treatment options.

Source note: This article includes information reported by Indiana Public Media.